MedTrace Logo

Procalcitonin Increase Identifies Critically Ill Patients at High Risk of Mortality

NCT00144638 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2005-09-05

No results posted yet for this study

Summary

Procalcitonin, a marker of infection has often been compared to clinical pictures as for instance "clinical sepsis". This has given som problems in the interpretation of these studies, because of the lack of good Gold Standards for "clinical sepsis. We have decided to investigate the development from day to day of Procalcitonin in the blood of intensive care patients, compared to the mortality.

Hypothesis: Procalcitonin increase after reaching a certain level predicts mortality in the Intensive Care Unit.

Conditions

  • Sepsis - to Reduce Mortality in the Intensive Care Unit

Sponsors & Collaborators

  • Danish Procalcitonin Study Group

    lead OTHER

Principal Investigators

  • Lars Heslet, MD, MD.Sc. · Dept. 4131, Rigshospitalet, Blegdamsvej 9, DK-2100

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Completion
2003-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144638 on ClinicalTrials.gov